The next medical breakthrough is most likely under development right now in an early-stage biotech company. The question is, will we ever see it on the market? That will depend on the company’s access to capital, continued investment and thoughtful strategic alliances. Every fall emerging private and public biotech companies gather with investors, research analysts, investment bankers and industry executives at the BIO Investor Forum in San Francisco to forge the lasting relationships that could change the medical landscape and perhaps bring the next groundbreaking cure or treatment to the market.
The conference, now in its 16th year, provides a diverse program of workshops, panel discussions and fireside chats focused on trends in finance, public policy and technology. Complementing and reinforcing the forum’s program is BIO’s One-on-One™ Partnering™ —a proprietary software that schedules meetings for participants at the event. These one-on-one interactions can prove immensely valuable to investors looking to invest in promising new drugs or devices. At the same time, they allow companies to demonstrate what differentiates them from the pack.
2016 BIO Investor Forum Post-Event Survey:
“Great mix of different investors and well executed format.”
“Good opportunity to meet with investors and Pharma representatives and establish relationships that may eventually lead to a partnership.”
“One-on-One meeting is the best mechanism for meeting potential investors and collaborators.”
“Panel sessions are interesting and informative.”
Partnering meetings are held in private rooms for 30 minutes and are arranged by BIO prior to the event. Last year over 2,000 meetings were held in just two days during the conference—a number that reflects this meeting’s importance for both investors and companies alike. The program has grown consistently as more attendees recognize the benefits of the personal connections made through it.
Record Level Investor Participation
Investor registration for the BIO Investor Forum is pacing well ahead of last year, indicating a continued interest in making deals or at least starting a conversation. The meeting will boast the largest ever number of investors signed up to attend, including these heavyweights:
New Enterprise Associates
A complete list of registered investors is on the website; new names are being added daily.
2016 BIO Investor Forum Post-Event Survey:
“Good meetings and networking opportunities. Meeting is a good size. Don’t make it too much bigger.”
“Convenient to have so many investors and companies in one place at the same time.”
“Excellent forum for meeting investors or alliance partners for biotech deals.”
“Good discussions and presentations.”
“…like being at JPM without the crowds.”
“Only national-level biotech conference catering to private and small cap public companies.”
Fifteen-minute presentations from nearly 170 biotech companies, nonprofit groups and philanthropy organizations will showcase efforts in their respective areas of interest. A unique opportunity is offered to young companies seeking first-round financing in the “Discovery Track Presentations” section of the program. For a reduced rate, “pre-emerging” biotech companies—those in Seed and A-round financing who have raised less than $25M total through October 2017—will have the opportunity to present to public and private equity investors, research analysts, investment bankers and industry executives.
The list of presenting companies is updated regularly.
Although the official BIO Investor Forum begins on Tuesday, Oct. 17, a special “SPARK Showcase will be offered on Monday, Oct. 16. Academic researchers will introduce their technology to an audience of venture funding companies and others in the biotech space. During the day-long event, academics interested in partnering will present their programs and have one-on-one discussions with interested parties.
The 2017 BIO Investor Conference will be held Oct. 17-18 at the Westin St. Francis Hotel in San Francisco. As in prior years, the forum will include plenary sessions, business roundtables, therapeutic workshops and fireside chats featuring respected industry veterans discussing the latest trends in biotech.
Advance media registration is available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.
Visit us to learn more about the BIO Investor Forum, including registration, programming, company presentations and partnering information.